



## **Imprimis Pharmaceuticals' Formulations to be Highlighted at Upcoming Annual Ophthalmology Meeting in Chicago**

October 13, 2016

SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the production and dispensing of high-quality innovative compounded medications, today announced events featuring its ophthalmic formulations at the annual American Academy of Ophthalmology (AAO) meeting held October 15-18 in Chicago, IL. AAO, a global community of 32,000 members, is the world's largest association of eye physicians and surgeons.



Mark L. Baum, CEO of Imprimis, stated, "We are very pleased to join the ophthalmology community at the annual AAO meeting. Based on the continuously growing interest and use of our innovative ophthalmic drug formulations, including Droplless Therapy, LessDrops and IV Free MKO Melt, we welcome the opportunity to share the experiences of a key group of experts currently using our formulations and introduce the latest additions to our product portfolio. The meeting's sessions will highlight the clinical benefits of our formulations and the convenience their use provides physicians and patients. The cost savings to patients, physicians, surgical centers and hospitals where ophthalmic surgeries are performed support our vision of making innovative drug formulations accessible to patients at affordable prices."

Imprimis will host an Open House on Friday, October 14, 2016 from 5:00 pm - 7:00 pm at the Hyatt Regency McCormick Place, Dusabel AB/CC21AB. CEO Mark L. Baum and distinguished ophthalmologists will discuss Imprimis and its ophthalmic formulations, including Droplless Therapy, LessDrops, and IV Free conscious sedation, as well as introduce new formulations. Faculty members will include John P. Berdahl, MD (Sioux Falls, SD), Chris J. Bender, CRNA (Sioux Falls, SD), Jeffrey T. Liegner, MD (Sparta, NJ), Sydney Tyson, MD (Vineland, NJ), William F. Wiley, MD (Cleveland, OH), Ahad Mahootchi, MD (Zephyrhills, FL), and Richard L. Lindstrom, MD (Minneapolis, MN). To register for the event, please visit [www.imprimisrx.com/aao2016](http://www.imprimisrx.com/aao2016).

Imprimis' ophthalmic formulations will be also discussed at several sessions during the AAO meeting. Please visit [www.imprimisrx.com/ophthalmologytalks](http://www.imprimisrx.com/ophthalmologytalks).

Additional information about Imprimis and its proprietary innovative ophthalmic treatment options and the events at the AAO 2016 meeting will be available to conference attendees on the showroom floor at Booth #362.

### **Imprimis' Droplless Therapy Injectable and LessDrops Topical Formulations**

Patient compliance is of utmost importance and Imprimis believes its LessDrops formulations can help to alleviate patient compliance issues commonly reported after ocular surgery. The sterile ophthalmic formulations are enabled by the company's patent-pending SSP Technology®, which allows for active pharmaceutical ingredients that ordinarily do not mix to solubilize into a predictable, well-distributed, micronized particle suspension. The drug formulations are optimized for isotonicity and pH most compatible for ophthalmic use, either as injectable or topical therapies. Every batch is tested for sterility prior to distribution and a complimentary copy of the test report is included with each prescription.

Imprimis' Dropless Therapy compounded antibiotic and steroid formulations are available in single, injectable intraocular doses administered by physicians following ocular surgery. Dropless Therapy may substantially reduce or eliminate the need for patient-administered eye drops following surgery, thereby largely eliminating patient non-compliance and dosing errors associated with post-operative care regimens. Dropless Therapy can simplify the post-operative care process, provide safeguards against bacterial infection and inflammation and decrease overall costs. More information is available at [www.GoDropless.com](http://www.GoDropless.com).

The company's LessDrops combination topical eye drops can significantly reduce the need for multiple postoperative drops required after ocular surgeries and, in turn, help to reduce medication costs. Developed with patients' top-of-mind, LessDrops combination formulations aim to improve patient compliance and alleviate patient confusion with fewer drops, thereby better enabling patients to follow their prescribed post-operative regimen. The LessDrops portfolio includes combination steroid, antibiotic and non-steroidal anti-inflammatory topical drops for patient administration following LASIK, cataract and other ocular surgeries. For more information, please visit [www.LessDrops.com](http://www.LessDrops.com).

#### **Imprimis' IV Free MKO Melt**

The IV Free MKO Melt (midazolam, ketamine and ondansetron) compounded conscious sedation formulation is an alternative option to IV anesthetic that is administered sublingually to sedate patients undergoing ocular and other surgical procedures. The MKO Melt, in troche format, provides consistent and predictable dosing and allows for quick and easy administration, resulting in increased positive experiences for patients and staff. Traditionally, sedation medications for ocular surgery have been administered intravenously, which requires IV medications and supplies, and the need for additional staff to assist in preparation, administration and monitoring related to this process; all of these factors often cause delays and disruptions in the operating room. The formulations or variations thereof have been used in over 8,000 LASIK, cataract and other surgeries to date and a growing number of physicians have made the switch to IV Free conscious sedation which are now available for the low cost of \$25.00 per two troche pack. For more information and to order the IV Free MKO Melt compounded formulation, please visit [www.IVFree.com](http://www.IVFree.com).

#### **About Imprimis Pharmaceuticals**

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states. The company's unique business model drives patient access and affordability to many critical medicines. Headquartered in San Diego, California, Imprimis owns and operates three dispensing facilities located in California New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at [www.ImprimisRx.com](http://www.ImprimisRx.com).

#### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at [www.sec.gov](http://www.sec.gov). Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

*All Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.*

#### **Media Contact**

Deb Holliday  
[deb@pascallecommunications.com](mailto:deb@pascallecommunications.com)  
412-877-4519

#### **Investor Contact**

Bonnie Ortega  
[bortega@imprimispharma.com](mailto:bortega@imprimispharma.com)  
858.704.4587

Logo - <http://photos.prnewswire.com/prnh/20150108/167712LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-formulations-to-be-highlighted-at-upcoming-annual-ophthalmology-meeting-in-chicago-300344145.html>

SOURCE Imprimis Pharmaceuticals, Inc.